Vor Biopharma Valuation
| VOR Stock | USD 2.05 0.16 7.24% |
Based on Macroaxis valuation methodology, the company appears to be overvalued. Vor Biopharma has a current Real Value of $1.07 per share. The regular price of the company is $2.05. Our model measures the value of Vor Biopharma from inspecting the company fundamentals such as Return On Equity of -1.25, shares outstanding of 124.96 M, and Shares Owned By Institutions of 48.45 % as well as reviewing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Vor Biopharma's price fluctuation is out of control at this time. Calculation of the real value of Vor Biopharma is based on 3 months time horizon. Increasing Vor Biopharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Vor stock is determined by what a typical buyer is willing to pay for full or partial control of Vor Biopharma. Since Vor Biopharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Vor Stock. However, Vor Biopharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.05 | Real 1.07 | Hype 2.46 | Naive 1.43 |
The intrinsic value of Vor Biopharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Vor Biopharma's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Vor Biopharma helps investors to forecast how Vor stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Vor Biopharma more accurately as focusing exclusively on Vor Biopharma's fundamentals will not take into account other important factors: Vor Biopharma Total Value Analysis
Vor Biopharma is at this time estimated to have company total value of 246.91 M with market capitalization of 276.16 M, debt of 31.83 M, and cash on hands of 151.09 M. Please note that company total value may be misleading and is a subject to accounting gimmicks. We encourage investors to carefully check all of the Vor Biopharma fundamentals before making security assessment based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
246.91 M | 276.16 M | 31.83 M | 151.09 M |
Vor Biopharma Asset Utilization
One of the ways to look at asset utilization of Vor is to check how much profit was generated for every dollar of assets it reports. Vor Biopharma has a negative utilization of assets of -0.55 %, losing $0.005525 for each dollar of assets held by the company. Inadequate asset utilization indicates the company is being less effective with each dollar of assets it has. In other words, asset utilization of Vor Biopharma shows how discouraging it operates for each dollar spent on its assets.Vor Biopharma Ownership Allocation
Vor Biopharma shows a total of 124.96 Million outstanding shares. Vor Biopharma maintains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.Vor Biopharma Profitability Analysis
Reported Net Loss for the year was (116.91 M) with profit before taxes, overhead, and interest of 0.About Vor Biopharma Valuation
The stock valuation mechanism determines Vor Biopharma's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Vor Biopharma based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Vor Biopharma. We calculate exposure to Vor Biopharma's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Vor Biopharma's related companies.Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell therapies for cancer patients. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. Vor Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 135 people.
Vor Biopharma Growth Indicators
Investing in growth stocks can be very risky. If the company such as Vor Biopharma does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 68.7 M |
Additional Tools for Vor Stock Analysis
When running Vor Biopharma's price analysis, check to measure Vor Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vor Biopharma is operating at the current time. Most of Vor Biopharma's value examination focuses on studying past and present price action to predict the probability of Vor Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vor Biopharma's price. Additionally, you may evaluate how the addition of Vor Biopharma to your portfolios can decrease your overall portfolio volatility.